 |
|
Acceleration of Wound Healing With Topically Applied Deoxyribonucleosides
E. Alexandria Chen, MD;
Lily Zhao, MD;
Michael Bamat, PhD;
Reid von Borstel, PhD;
Thomas Mustoe, MD
Arch Surg. 1999;134:520-525.
Hypothesis We hypothesized that a topical mixture of purified deoxyribonucleosides would accelerate wound healing in an open wound model.
Design Full-thickness 6-mm wounds were made on the ears of young adult rabbits. In some experiments, 2 of the 3 arteries in each ear were divided to induce wound ischemia.
Interventions An equiweight mixture containing all 4 of the major deoxyribonucleosides (deoxyadenosine, deoxycytidine, deoxyguanosine, and thymidine), designated PN105, or other subgroups of deoxyribonucleosides, or vehicle (saline) was applied to wounds on 1 ear every 2 days, with the other ear serving as a control.
Main Outcome Measures Wound tissue was processed for histological examination 7 days after the initial wounding. Granulation tissue formation and epithelialization were measured in histological cross sections of wounds.
Results Treatment of wounds with PN105 resulted in a 191% increase in total new granulation tissue (P<.05) and a higher incidence of complete wound reepithelialization (67% vs 37%; P<.05) when compared with controls, and a similar increase under ischemic conditions on day 7. Wound ischemia markedly impairs healing; PN105 treatment resulted in a 242% increase in the amount of new granulation tissue formed by day 7 in ischemic wounds, relative to the appropriate controls (P<.05). All 4 of the major deoxyribonucleosides were required for optimum activity; mixtures with 3 or 2 were less active or inactive.
Conclusions Topically applied deoxyribonucleosides reproducibly accelerate wound healing in normal and ischemic wounds, and to a magnitude equivalent to that of recombinant growth factors such as platelet-derived growth factor, previously studied in this model. In view of their safety, availability, and efficacy, deoxyribonucleosides hold considerable promise for improving healing of chronic wounds.
From the Division of Plastic Surgery, Northwestern Medical School, Chicago, Ill (Drs Chen, Zhao, and Mustoe); and Pro-Neuron Inc, Gaithersburg, Md (Drs Bamat and von Borstel). Drs Bamat and von Borstel are employees of Pro-Neuron Inc. Pro-Neuron Inc owns the rights to and supplied the PN105 wound healing agent for the studies reported in this article.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Identification of Wound Healing/Regeneration Quantitative Trait Loci (QTL) at Multiple Time Points that Explain Seventy Percent of Variance in (MRL/MpJ and SJL/J) Mice F2 Population
Masinde et al.
Genome Res 2001;11:2027-2033.
ABSTRACT
| FULL TEXT
|
